Promoted Content

Promoted Content

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Reset Filter

All Drugs in Dev.

Product Type

Companies

PeptiDream

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Post An Enquiry

German Biotechnology Days 2021

Participation Not Confirmed

Update your events

Alnylam and PeptiDream Enter into Collaboration Agreement

Lead Product(s): Peptide-siRNA Conjugates

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Peptide

Partner/Sponsor/Collaborator: Alnylam Pharmaceuticals

Deal Size: $2,200.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration July 27, 2021

Details:

PeptiDream will select, optimize, and synthesize peptides for each receptor. Alnylam will then generate peptide-siRNA conjugates and perform in vitro and in vivo studies to support final peptide selection.